Tesamorelin reduces visceral fat by stimulating the body's own production of growth hormone. Growth hormone has lipolytic effects, meaning it promotes the breakdown of fat. It increases the rate at which fat is broken down and released into the bloodstream, and also increases the metabolic rate, which helps the body burn more calories and fat.

Tesamorelin reduces visceral fat by increasing the body's natural growth hormone (GH) production through activation of growth hormone-releasing hormone (GHRH) receptors in the pituitary gland. As GH levels rise, the body produces more insulin-like growth factor-1 (IGF-1), which helps to increase lipolysis, the process of breaking down stored fat and using it for energy. This effect is particularly noticeable in visceral adipose tissue (VAT), which is the deep abdominal fat surrounding internal organs [1–4]. Unlike many weight loss methods that reduce body weight more generally, tesamorelin primarily focuses on reducing harmful visceral fat while preserving subcutaneous fat and lean muscle mass [2–5].

Visceral fat behaves differently from subcutaneous fat located under the skin. It is more metabolically active, more strongly associated with inflammation and metabolic diseases, and more sensitive to growth hormone signaling. Visceral adipose tissue contains a large number of GH-sensitive receptors and exhibits stronger fat-burning activity at higher levels of GH and IGF-1. Tesamorelin increases the body's natural pulsatile GH secretion, which activates hormone-sensitive lipase and other enzymes responsible for breaking down triglycerides stored in visceral fat cells [1–4]. The released fatty acids are then utilized by the body as an energy source, helping to reduce deep abdominal fat stores over time.

Clinical trials in humans have consistently shown that tesamorelin significantly reduces the amount of visceral abdominal fat. In a placebo-controlled study conducted by Falutz J et al. (2005), HIV-positive adults with abdominal fat accumulation who received tesamorelin experienced a significant reduction in visceral adipose tissue after 12 weeks of treatment [4]. Participants receiving 2 mg daily achieved approximately a 15.71% reduction in visceral fat, along with improved triglyceride levels and an increase in lean body mass, while subcutaneous fat remained relatively stable.

Similar results were reported by Falutz J et al. (2007), who demonstrated that tesamorelin reduced harmful visceral abdominal fat by approximately 15% over 26 weeks in individuals with HIV-associated lipodystrophy [5]. Lipodystrophy refers to an abnormal redistribution of fat that can occur in some individuals receiving antiretroviral therapy. The study also demonstrated a reduction in waist circumference and an improvement in the lipid profile without a significant deterioration in glucose metabolism. These results suggest that increasing endogenous GH production may selectively reduce metabolically harmful visceral fat deposits.

Long-term Phase III clinical trials have confirmed that these effects may persist with continued treatment. In a large, multicenter pooled analysis conducted by Falutz J et al. (2010), tesamorelin reduced visceral fat by approximately 15.4% among 806 HIV-positive participants receiving 2 mg daily [6]. The researchers also observed improvements in waist circumference, waist-to-hip ratio, triglyceride levels, and body image. Importantly, participants who discontinued tesamorelin treatment gradually regained visceral fat, suggesting that continued stimulation of GH pathways may be necessary to maintain these benefits.

Studies also suggest that tesamorelin may improve the quality and metabolic behavior of visceral adipose tissue. Stanley TL et al. (2012) demonstrated that participants who achieved at least an 8% reduction in visceral adipose tissue also experienced improvements in triglyceride levels, adiponectin, and overall markers of metabolic health [7]. Adiponectin is a hormone produced by adipose tissue that supports insulin sensitivity and helps reduce inflammation associated with visceral obesity.

In addition to reducing abdominal fat, tesamorelin also appears to affect fat accumulation in the liver, which is closely linked to visceral obesity and metabolic disorders. Stanley TL et al. (2014) demonstrated that tesamorelin significantly reduced both visceral abdominal fat and liver fat content in HIV-positive individuals with excess abdominal fat [8]. Liver fat refers to fat accumulating within the liver. Similarly, randomized trials on HIV-associated non-alcoholic fatty liver disease (NAFLD) showed that tesamorelin reduced hepatic fat by approximately 37% relative to baseline values, while simultaneously improving the expression of mitochondrial and metabolic genes in the liver [9,10]. Mitochondria are structures responsible for energy production in cells, so these results may reflect an improvement in cellular energy metabolism.

Certain metabolic factors may influence the strength of the body's response to tesamorelin therapy. Mangili A et al. (2015) demonstrated that individuals with metabolic syndrome, obesity, elevated triglyceride levels, and higher cardiovascular risk markers tended to experience greater visceral fat reduction during treatment [11]. Tesamorelin users were more likely to reduce visceral fat levels below thresholds associated with increased cardiovascular risk.

The effect of tesamorelin on visceral fat also appears to be consistent regardless of the fat distribution pattern. Rahman F et al. (2023) demonstrated that tesamorelin reduced visceral fat to a similar extent in HIV-positive individuals both with and without neck fat accumulation, commonly referred to as a „buffalo hump” [12]. Participants in both groups experienced nearly identical reductions in visceral adipose tissue and waist circumference, suggesting that tesamorelin can effectively reduce deep abdominal fat regardless of other fat redistribution patterns.

In general, tesamorelin reduces visceral fat by stimulating the body's natural production of GH and IGF-1 via physiological GHRH signaling pathways. Increased growth hormone activity enhances the breakdown of fat in metabolically active abdominal fat depots, leading to reduced visceral fat, improved lipid metabolism, decreased liver fat, and broader metabolic benefits. Clinical trials have consistently demonstrated that tesamorelin preferentially targets harmful visceral fat while preserving lean body mass and maintaining relatively stable glucose control [4–12]. Tesamorelin used in laboratory studies is available from suppliers such as SemaxPolska. Please note that study results refer to controlled scientific conditions and do not confirm clinical efficacy in other applications.

Disclaimer

The content is for educational and scientific-informational purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin is a prescription medication primarily approved for the treatment of HIV-associated lipodystrophy. Therapies affecting growth hormone and metabolic pathways require medical supervision, laboratory monitoring, and individual clinical assessment by a qualified healthcare professional.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: NCBI Bookshelf: Tesamorelin Overview
2. PubChem. (2025). Tesamorelin Compound Summary. National Center for Biotechnology Information. Available at: PubChem Tesamorelin Summary
3. Stanley TL, Chen, C. Y., Branch, K. L., et al. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. The Journal of Clinical Endocrinology & Metabolism, 96(1), 150–158. https://doi.org/10.1210/jc.2010-1586
4. Falutz J, Allas, S., Kotler, D., et al. (2005). Placebo-controlled dose-ranging study of a growth hormone-releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS, 19(12), 1279–1287. https://doi.org/10.1097/01.aids.0000180099.35146.30
5. Falutz J, Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
6. Falutz J, Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
7. Stanley TL, Falutz, J., Marsolais, C., et al. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 54(11), 1642–1651. https://doi.org/10.1093/cid/cis251
8. Stanley TL, Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
9. Fourman LT, Billingsley, J. M., Agyapong, G., Ho Sui, S. J., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Corey, K. E., Torriani, M., Kleiner, D. E., Hadigan, C. M., Stanley, T. L., Chung, R. T., & Grinspoon, S. K. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16), e140134. https://doi.org/10.1172/jci.insight.140134
10. Stanley TL, Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
11. Mangili A, Falutz, J., Mamputu, J. C., Stepanians, M., & Hayward, B. (2015). Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS ONE, 10(10), e0140358. https://doi.org/10.1371/journal.pone.0140358
12. Rahman F, McLaughlin, T., Mesquita, P., Morin, J., Potvin, D., De Chantal, M., & Aberg, J. A. (2023). Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of Clinical and Translational Science, 7(1), e40. https://doi.org/10.1017/cts.2022.515